Free Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Vontobel Holding Ltd.

Regeneron Pharmaceuticals logo with Medical background

Vontobel Holding Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,339 shares of the biopharmaceutical company's stock after purchasing an additional 881 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $4,655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of REGN. Brighton Jones LLC raised its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the period. US Bancorp DE increased its position in Regeneron Pharmaceuticals by 21.6% during the 4th quarter. US Bancorp DE now owns 6,066 shares of the biopharmaceutical company's stock valued at $4,321,000 after purchasing an additional 1,078 shares during the period. Jones Financial Companies Lllp increased its position in Regeneron Pharmaceuticals by 107.7% during the 4th quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company's stock valued at $578,000 after purchasing an additional 421 shares during the period. Steward Partners Investment Advisory LLC increased its position in Regeneron Pharmaceuticals by 26.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $3,296,000 after purchasing an additional 981 shares during the period. Finally, Commerzbank Aktiengesellschaft FI increased its position in Regeneron Pharmaceuticals by 49.5% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 601 shares of the biopharmaceutical company's stock valued at $423,000 after purchasing an additional 199 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $9.25 during trading hours on Monday, reaching $538.11. 959,668 shares of the company's stock were exchanged, compared to its average volume of 907,598. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a market capitalization of $58.10 billion, a P/E ratio of 13.70, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33. The business has a fifty day moving average of $547.93 and a two-hundred day moving average of $623.60. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.55 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

View Our Latest Analysis on REGN

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines